Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call on March 8, 2023

Rhea-AI Summary

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) will announce its fourth quarter and year-end 2022 financial results on March 8, 2023, at 4:30 p.m. ET. The company will host a conference call to discuss these results along with recent corporate developments. Participants can join the conference call by dialing 1 833 927 1758 in the U.S. or 1 929 526 1599 internationally, with the passcode 596100. The call will also be available via webcast on Mirum's website for 30 days post-event. Mirum focuses on treatments for rare liver diseases, including its approved medication LIVMARLI®.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report fourth quarter and year-end 2022 financial results on Wednesday, March 8, 2023. Mirum will also host a conference call to discuss the fourth quarter and year-end 2022 financial results and recent corporate progress.

Conference call details:
Wednesday, March 8, 2023
4:30 p.m. ET / 1:30 p.m. PT

Dial-in:
U.S./Toll-Free: 1 833 927 1758
International: 1 929 526 1599
Passcode: 596100

You may also access the call via webcast by visiting the Events & Presentations section on Mirum’s website. A replay of this webcast will be available for 30 days.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older, and in Europe for the same indication in patients two months of age and older.

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. LIVMARLI, an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the EMBARK Phase 2b clinical trial for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.

Mirum’s second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in two potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis.

Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005320/en/

Investor Contacts:

Andrew McKibben

investors@mirumpharma.com

Sam Martin

Argot Partners

ir@mirumpharma.com

Media Contact:

Erin Murphy

media@mirumpharma.com

Source: Mirum Pharmaceuticals, Inc.

FAQ

When will Mirum Pharmaceuticals report its financial results?

Mirum Pharmaceuticals will report its fourth quarter and year-end 2022 financial results on March 8, 2023.

What time is the Mirum Pharmaceuticals conference call?

The conference call will take place at 4:30 p.m. ET on March 8, 2023.

How can I access the Mirum Pharmaceuticals conference call?

The conference call can be accessed by dialing 1 833 927 1758 in the U.S. or 1 929 526 1599 internationally, using passcode 596100, or via webcast on Mirum's website.

What is Mirum Pharmaceuticals' stock symbol?

Mirum Pharmaceuticals is listed on NASDAQ under the stock symbol MIRM.

What treatments does Mirum Pharmaceuticals offer?

Mirum Pharmaceuticals offers LIVMARLI® for treating rare liver diseases and is developing additional investigational treatments.